Stock Movers Pfizer 4Q Revenue Beats; Merck’s Forecast Misses Expectations; PepsiCo Pledging to Cut Some Prices
Feb 3, 2026
Market movers: Pfizer topped Q4 revenue forecasts and held guidance. Merck cut its 2026 forecast amid Gardasil setbacks in China and dose changes. PepsiCo beat profit estimates, announced a $10 billion buyback and plans selective price cuts. Rapid growth at Palantir and its upbeat sales outlook also made headlines.
AI Snips
Chapters
Transcript
Episode notes
Pfizer Beats Estimates And Advances GLP-1
- Pfizer beat fourth-quarter sales estimates and held full-year guidance, driven partly by COVID-19 product revenue.
- The company also reported positive trial results for a monthly-dosed ultra-long GLP-1 weight-loss drug, which could expand the market.
Merck Guidance Hurt By Gardasil Headwinds
- Merck beat fourth-quarter results but guided 2026 sales below analysts' expectations, citing Gardasil headwinds in China and the U.S.
- The company is assuming no Gardasil shipments to China in its guidance, pressuring near-term sales and shares.
PepsiCo Cuts Prices And Buybacks
- PepsiCo plans price cuts to address consumer pushback about high prices and regain volume lost to cheaper brands.
- The company also announced a $10 billion buyback after reporting a slight earnings beat, balancing pricing moves with shareholder returns.